anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Afamelanotide
Trial phase: Phase 3
ATC code: D02BB02
SMILES: CCCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(C)=O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(N)=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.

Afamelanotide
Eligibility criteria:
Inclusion Criteria:

Aged greater than 18 years
Male or female patients with a documented history of PLE diagnosed or confirmed by a photodermatologist or photobiologist, with a history of PLE related pruritus symptoms.
Recurrent PLE episodes that occur at least once a year (as evidenced by PLE related pruritus symptoms) developing in their own country (to exclude patients affected only when traveling to sunnier climates)
Written informed consent prior to the performance of any study-specific procedure
Are willing and able to comply with the conditions specified in the protocol and study procedures in the opinion of the Investigator

Exclusion Criteria:

Currently requiring treatment with systemic immunosuppressive agents
Documented history of other photosensitivity conditions which may be confused with PLE or interfere with the assessment of PLE episodes
Solarium use in the three months prior to study involvement and throughout the duration of the study
Use of immunosuppressive medications, drugs that cause hyperpigmentation or any other treatment that in the opinion of the Investigator may interfere with this study
Documented presence (> 1 in 320) of Anti-Nuclear Antibody (ANA) and/or positive Extractable Nuclear Antibody (ENA); historical results from the 3 years prior to randomisation are acceptable if available
In the opinion of the Investigator, any evidence of clinically significant organ dysfunction, or any clinically significant deviation from normal in clinical or laboratory parameters
History of drug or alcohol abuse (in the last 1 year)
Female who is pregnant (confirmed by positive serum beta-Human chorionic gonadotropin (β-HCG) pregnancy test prior to baseline) or lactating
Female of child-bearing potential (pre-menopausal, not surgically sterile) that is not using or is not willing to use adequate contraceptive measures (e.g. oral contraceptives, condoms, diaphragm plus spermicide, intrauterine device)
Sexually active men with partners of child bearing potential not willing to use barrier contraception during the trial and for a period of three months thereafter
Participation in a clinical trial with another Investigational Medicinal Product (IMP) within 30 days prior to the Screening visit or during the study
Hypersensitivity to afamelanotide or any of its components
Intervention: Suvorexant
Trial phase: Phase 4
ATC code: N05CJ01 | N05CM19
SMILES: [H][C@@]1(C)CCN(c2nc3cc(Cl)ccc3o2)CCN1C(=O)c1cc(C)ccc1-n1nccn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Participants in both arms of the study received suvorexant treatment, either during treatment one or treatment two.
Eligibility criteria:
Inclusion Criteria:

Men or women of any ethnic origin
Written informed consent is obtained
Speaks and writes in English
A willingness and ability to comply with study procedures
Age 25-85 years
Diagnosis of RLS via Cambridge-Hopkins RLS questionnaire
International Restless Legs Syndrome Study Group scale score (IRLS) < 15
RLS treatment with a dopaminergic agonist or an alpha-2-delta agent
No changes in RLS medication in the previous month
DSM-5 criteria for Insomnia Disorder
Report a total sleep time ≤ 7 hours and wake after sleep onset (WASO) > 45 minutes on 7 or more of the 14 nightly sleep logs during both the initial 2-week screening period and the two-week screening run-in period. WASO does not decrease by more than 50% on the 2-week sleep diary obtained between the screening visit and the randomization visit

Exclusion Criteria:

Diagnosis of moderate/severe obstructive sleep apnea (AHI > 30) not using continuous positive airway pressure therapy (CPAP) (can be included if CPAP adherent), or other untreated primary sleep disorders (e.g. narcolepsy)
Shift workers
Unwillingness to not use sedative-hypnotics (other than suvorexant) during the study period
Unwillingness to maintain stable RLS medication during the study unless medically indicated
Current use of an opiate medication
Unwillingness to not take stimulants (e.g. caffeine) after 4:00 pm during the study
Current major depressive episode, by report and as indicated by the Patient Health Questionnaire (PHQ-9)
Lifetime history of bipolar disorder, psychosis, or other serious psychiatric illness
Current alcohol/substance use disorder
BMI ≥ 40 kg/m^2
Renal or hepatic disease judged to interfere with drug metabolism and excretion
Pregnancy or breastfeeding
Malignancy within past 2 years
Surgery within past 3 months
Neurological disorder or cardiovascular disease raising safety concerns about use of suvorexant and/or judged to interfere with ability to assess efficacy of the treatment
Medical instability considered to interfere with study procedures
Concomitant medications with drug interaction or co-administration concerns
Contraindications or allergic responses to suvorexant
History of being treated with suvorexant
Travel across two time-zones during the week prior to enrollment
Greater than 6 cups of coffee per day
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 534
Group description: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68.
Eligibility criteria:
Inclusion Criteria:

Male or female, age above or equal to 18 years at the time of signing informed consent.
Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of screening.
HbA1c of 8.0-10.5% (64-91 mmol/mol) (both inclusive).
BMI equal to or above 25 kg/m^2
Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:

No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:

Metformin (equal to or above1500 mg or maximum tolerated or effective dose).
Sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose).
Sodium/glucose cotransporter 2 (SGLT2) inhibitors (maximum tolerated dose).
Dipeptidyl peptidase-4 (DPP-4) inhibitors (maximally indicated dose as per local label).
Subjects, on treatment with stable dose of DPP-4 inhibitors at inclusion, must be willing to discontinue DPP-4 inhibitor treatment at randomisation (with no wash-out).

Exclusion Criteria:

Treatment with any medication indicated for the treatment of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed.
Renal impairment measured as estimated glomerular filtration rate (eGFR) value of below 30 mL/min/1.73 m^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO 2012) classification.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 534
Group description: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68.
Eligibility criteria:
Inclusion Criteria:

Male or female, age above or equal to 18 years at the time of signing informed consent.
Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of screening.
HbA1c of 8.0-10.5% (64-91 mmol/mol) (both inclusive).
BMI equal to or above 25 kg/m^2
Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:

No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:

Metformin (equal to or above1500 mg or maximum tolerated or effective dose).
Sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose).
Sodium/glucose cotransporter 2 (SGLT2) inhibitors (maximum tolerated dose).
Dipeptidyl peptidase-4 (DPP-4) inhibitors (maximally indicated dose as per local label).
Subjects, on treatment with stable dose of DPP-4 inhibitors at inclusion, must be willing to discontinue DPP-4 inhibitor treatment at randomisation (with no wash-out).

Exclusion Criteria:

Treatment with any medication indicated for the treatment of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed.
Renal impairment measured as estimated glomerular filtration rate (eGFR) value of below 30 mL/min/1.73 m^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO 2012) classification.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 534
Group description: Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68.
Eligibility criteria:
Inclusion Criteria:

Male or female, age above or equal to 18 years at the time of signing informed consent.
Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of screening.
HbA1c of 8.0-10.5% (64-91 mmol/mol) (both inclusive).
BMI equal to or above 25 kg/m^2
Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:

No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:

Metformin (equal to or above1500 mg or maximum tolerated or effective dose).
Sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose).
Sodium/glucose cotransporter 2 (SGLT2) inhibitors (maximum tolerated dose).
Dipeptidyl peptidase-4 (DPP-4) inhibitors (maximally indicated dose as per local label).
Subjects, on treatment with stable dose of DPP-4 inhibitors at inclusion, must be willing to discontinue DPP-4 inhibitor treatment at randomisation (with no wash-out).

Exclusion Criteria:

Treatment with any medication indicated for the treatment of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed.
Renal impairment measured as estimated glomerular filtration rate (eGFR) value of below 30 mL/min/1.73 m^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO 2012) classification.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Dexamethasone 20 mg daily for 5 days, followed by dexamethasone 10 mg daily for 5 days

Dexamethasone: Dexamethasone
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18 years old
RT-PCR confirmed COVID-19 infection
Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula (HFNC) or need supplemental oxygen with oxygen mask or nasal cannula

Exclusion Criteria:

Underlying disease requiring chronic corticosteroids
Severe adverse events before admission, i.e. cardiac arrest;
Contraindication for corticosteroids;
Death is deemed to be imminent and inevitable during the next 24 hours
Recruited in other clinical intervention trial
Pregnancy
Patient on judicial protection
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: Dexamethasone 6 mg daily for 10 days

Dexamethasone: Dexamethasone
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18 years old
RT-PCR confirmed COVID-19 infection
Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula (HFNC) or need supplemental oxygen with oxygen mask or nasal cannula

Exclusion Criteria:

Underlying disease requiring chronic corticosteroids
Severe adverse events before admission, i.e. cardiac arrest;
Contraindication for corticosteroids;
Death is deemed to be imminent and inevitable during the next 24 hours
Recruited in other clinical intervention trial
Pregnancy
Patient on judicial protection
Intervention: Bemnifosbuvir hemisulfate
Trial phase: Phase 2
SMILES: CNc1nc(N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OC(C)C)Oc2ccccc2)C(O)C1(C)F.CNc1nc(N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OC(C)C)Oc2ccccc2)C(O)C1(C)F.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants received 550 mg AT-527 (1x550 mg) twice a day (BID) on Days 1-5.
Eligibility criteria:
Inclusion Criteria:

Positive SARS-CoV-2 diagnostic test (RT-PCR or rapid antigen test)at screening
Has symptoms consistent with mild or moderate COVID-19, as determined by the investigator, with onset ≤5 days prior to randomization

Exclusion Criteria:

Clinical signs indicative of COVID-19 illness requiring hospitalization, defined as any of the following: shortness of breath at rest, respiratory rate ≥30, heart rate ≥125, peripheral capillary oxygen saturation ≤93% on room air
Treatment with a therapeutic agent against SARS-CoV-2 including, but not limited to, other direct acting antivirals, convalescent plasma, monoclonal antibodies against SARS CoV-2, or intravenous immunoglobulin within 3 months or less than 5 drug elimination half-lives (whichever is longer) prior to screening
Requirement, in the opinion of the investigator, for any of the prohibited medications during the study
Use of hydroxychloroquine or amiodarone within 3 months of screening
Pregnant or breastfeeding, or intending to become pregnant during the study or within 30 days after the final dose of AT-527. Women of childbearing potential must have a negative urine pregnancy test result at screening
Abnormal laboratory test results at screening
Clinically significant abnormal ECG, as determined by the Investigator, at screening
Planned procedure or surgery during the study
Known allergy or hypersensitivity to study drug or drug product excipients
Substance abuse, as determined by the investigator, within 12 months prior to screening
Poor peripheral venous access
Malabsorption syndrome or other condition that would interfere with enteral absorption
Any clinically significant history of epistaxis within the last 3 months and/or history of being hospitalized due to epistaxis of any previous occasion
History of anaphylaxis
Any uncontrolled serious medical condition or other clinically significant abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Intervention: Bemnifosbuvir hemisulfate
Trial phase: Phase 2
SMILES: CNc1nc(N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OC(C)C)Oc2ccccc2)C(O)C1(C)F.CNc1nc(N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OC(C)C)Oc2ccccc2)C(O)C1(C)F.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants received 1100 mg AT-527 (4x275 mg) twice a day (BID) on Days 1-5.
Eligibility criteria:
Inclusion Criteria:

Positive SARS-CoV-2 diagnostic test (RT-PCR or rapid antigen test)at screening
Has symptoms consistent with mild or moderate COVID-19, as determined by the investigator, with onset ≤5 days prior to randomization

Exclusion Criteria:

Clinical signs indicative of COVID-19 illness requiring hospitalization, defined as any of the following: shortness of breath at rest, respiratory rate ≥30, heart rate ≥125, peripheral capillary oxygen saturation ≤93% on room air
Treatment with a therapeutic agent against SARS-CoV-2 including, but not limited to, other direct acting antivirals, convalescent plasma, monoclonal antibodies against SARS CoV-2, or intravenous immunoglobulin within 3 months or less than 5 drug elimination half-lives (whichever is longer) prior to screening
Requirement, in the opinion of the investigator, for any of the prohibited medications during the study
Use of hydroxychloroquine or amiodarone within 3 months of screening
Pregnant or breastfeeding, or intending to become pregnant during the study or within 30 days after the final dose of AT-527. Women of childbearing potential must have a negative urine pregnancy test result at screening
Abnormal laboratory test results at screening
Clinically significant abnormal ECG, as determined by the Investigator, at screening
Planned procedure or surgery during the study
Known allergy or hypersensitivity to study drug or drug product excipients
Substance abuse, as determined by the investigator, within 12 months prior to screening
Poor peripheral venous access
Malabsorption syndrome or other condition that would interfere with enteral absorption
Any clinically significant history of epistaxis within the last 3 months and/or history of being hospitalized due to epistaxis of any previous occasion
History of anaphylaxis
Any uncontrolled serious medical condition or other clinically significant abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Intervention: Cipepofol
Trial phase: Phase 3
SMILES: CC(C)c1cccc(C(C)C2CC2)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 168
Group description: HSK3486 for induction of general anesthesia.

HSK3486: HSK3486 for induction of general anesthesia.
Eligibility criteria:
Inclusion Criteria:

Subjects undergoing elective surgery (nonemergency, noncardiothoracic, and nonintracranial surgery anticipated to last at least 1 hour ).
Males or females, aged ≥18 years old, with American Society of Anesthesiologists Physical Status (ASA PS) I to IV.
Body mass index (BMI) ≥18 kg/m2.
For all females of childbearing potential, negative pregnancy test at screening and baseline. Additionally, females of childbearing potential must agree to use birth control (such as condom, intrauterine device [IUD], abstinence) from the time of consent until 30 days post study drug administration.
Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form, and to complete this study in strict compliance with the study protocol.

Exclusion Criteria:

Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
Medical condition or evidence of increased sedation/general anesthesia risk.
Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study.
Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics.
Laboratory parameters significantly out of range at screening.
Female subjects with a positive pregnancy test (serum or urine) at screening or baseline; lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.